ATNM Stock Price, Actinium Pharmaceuticals Quote, Chart

Market Summary

USD8.73+0.95

Market Closed

12.21%

ATNM Stock Price

View Fullscreen

ATNM RSI Chart

ATNM Valuation

Market Cap

260.0M

Price/Earnings (Trailing)

-5.6

Price/Sales (Trailing)

3.2K

Price/Free Cashflow

-6.55

ATNM Price/Sales (Trailing)

ATNM Profitability

Return on Equity

-105.91%

Return on Assets

-52.57%

Free Cashflow Yield

-15.28%

ATNM Fundamentals

ATNM Revenue

ATNM Earnings

Earnings (TTM)

-46.5M

Earnings Growth (Yr)

21.45%

Earnings Growth (Qtr)

7.01%

Breaking Down ATNM Revenue

Last 7 days

33.1%

Last 30 days

1.5%

Last 90 days

64.7%

Trailing 12 Months

-2.7%

How does ATNM drawdown profile look like?

ATNM Financial Health

Current Ratio

10.59

ATNM Investor Care

Shares Dilution (1Y)

12.77%

Diluted EPS (TTM)

-1.71

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	555.5K	0	0	81.0K
2022	1.5M	1.2M	1.1M	1.0M
2021	0	690.2K	917.1K	1.1M
2012	236.5K	463.4K	0	0
2011	0	20.1K	14.9K	9.6K
2010	0	0	0	25.4K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Actinium Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 17, 2022	seth sandesh	acquired	-	-	300,000	chief executive officer
Mar 05, 2019	berger mark stanley	acquired	2,100	0.6	3,500	chief medical officer
Feb 21, 2019	seth sandesh	acquired	4,875	0.6	8,125	chairman & ceo

Which funds bought or sold ATNM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CREATIVE FINANCIAL DESIGNS INC /ADV	added	15.33	78,214	178,798	0.02%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	Mirae Asset Global Investments Co., Ltd.	sold off	-100	-72,568	-	-%
Apr 30, 2024	Retirement Group, LLC	unchanged	-	3,276	9,326	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	39.00	39.00	-%
Apr 29, 2024	HAZLETT, BURT & WATSON, INC.	sold off	-100	-1,000	-	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-46.92	-15,000	71,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-41.32	-55,759	527,477	-%
Apr 24, 2024	Hartford Financial Management Inc.	unchanged	-	731	2,083	-%
Apr 23, 2024	Gradient Investments LLC	sold off	-100	-335	-	-%

Are Funds Buying or Selling ATNM?

Are funds buying ATNM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ATNM

No. of Funds

Unveiling Actinium Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2024	bigger capital, llc	1.6%	441,104	SC 13G/A
Jan 29, 2024	blackrock inc.	6.2%	1,691,914	SC 13G
Feb 06, 2023	bigger capital fund l p	1.6%	416,000	SC 13G/A
Feb 09, 2022	bigger capital fund l p	1.5%	323,236	SC 13G/A
Feb 12, 2021	bigger capital fund l p	2.1%	292,729	SC 13G/A
Jan 05, 2021	sabby management, llc	4.64%	630,637	SC 13G/A
Aug 12, 2020	bigger capital fund l p	2.1%	287,730	SC 13G
May 01, 2020	sabby management, llc	7.29%	20,095,255	SC 13G
Apr 27, 2020	bigger capital fund l p	1.7%	6,448,693	SC 13G/A
Feb 14, 2020	bigger capital fund l p	1.9%	3,191,979	SC 13G/A

Recent SEC filings of Actinium Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	10-Q	Quarterly Report
Mar 29, 2024	S-8	Employee Benefits Plan
Mar 29, 2024	10-K	Annual Report
Feb 09, 2024	SC 13G/A	Major Ownership Report
Feb 05, 2024	EFFECT	EFFECT
Feb 02, 2024	S-3/A	S-3/A
Feb 02, 2024	CORRESP	CORRESP
Jan 29, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Actinium Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Actinium Pharmaceuticals Inc News

Latest updates

Actinium Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2012Q2	2012Q1	2011Q4	2011Q3	2011Q2	2010Q4	2010Q3	2010Q2
Revenue	-	-	-	-	-	45.00	45.00	940	23.00	233	266	178	90.00	2.00	2.00	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-7.9%	9,597	10,424	11,584	11,291	9,844	7,895	6,104	8,071	6,702	5,341	-	-	-	-	-	-	-	-
S&GA Expenses	-100.0%	-	2,306	3,735	3,958	3,073	3,233	1,735	2,655	1,994	1,710	-	-	-	-	-	-	-	-
R&D Expenses	-18.3%	6,635	8,118	7,849	7,333	6,771	4,662	4,369	5,416	4,708	3,631	-	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	1,019	547	644	325	83.00	35.00	38.00	46.00	54.00	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-561*	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	7.0%	-8,670	-9,324	-11,037	-10,647	-9,474	-7,767	-5,129	-8,010	-6,423	-5,021	-	-	-	-	-	-	-	-
Net Income Margin	4.8%	-573.47*	-602.69*	-70.07*	-32.06*	-28.85*	-22.02*	-16.81*	-21.66*	-25.24*	-32.25*	-	-	-	-	-	-	-	-
Free Cashflow	1.4%	-7,385	-7,490	-15,153	-7,794	-5,788	27,648	-5,788	-5,052	-5,656	-4,645	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	8.5%	88.00	81.00	89.00	99.00	102	114	117	122	75.00	80.00	84.00	84.00	75.00	66.00	51.00	56.00	8.00	12.00	16.00	22.00	12.00
Current Assets	9.1%	85.00	78.00	86.00	96.00	99.00	111	113	118	74.00	80.00	83.00	83.00	74.00	65.00	49.00	55.00	7.00	10.00	15.00	20.00	10.00
Cash Equivalents	10.0%	84.00	77.00	83.00	91.00	95.00	109	113	117	72.00	78.00	82.00	82.00	73.00	64.00	49.00	54.00	6.00	10.00	15.00	20.00	10.00
Net PPE	-9.8%	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-1.3%	44.00	45.00	45.00	46.00	45.00	48.00	46.00	44.00	6.00	7.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	6.00	6.00	6.00	7.00
Current Liabilities	-5.1%	8.00	8.00	9.00	9.00	8.00	11.00	8.00	6.00	6.00	7.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	5.00	6.00	5.00	6.00
Shareholder's Equity	20.6%	44.00	36.00	44.00	53.00	57.00	66.00	71.00	78.00	69.00	74.00	80.00	80.00	71.00	61.00	45.00	51.00	3.00	6.00	10.00	16.00	5.00
Retained Earnings	-2.6%	-346	-337	-328	-314	-299	-288	-278	-268	-260	-255	-247	-241	-236	-230	-224	-219	-214	-208	-204	-197	-192
Additional Paid-In Capital	4.3%	390	374	372	368	357	355	349	347	330	329	328	322	307	292	270	270	217	214	214	213	198
Accumulated Depreciation	9.5%	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Shares Outstanding	6.4%	29.00	28.00	27.00	27.00	26.00	26.00	24.00	23.00	22.00	22.00	20.00	19.00	19.00	18.00	-	-	-	-	-	-	-
Float	-	-	-	-	200	-	-	-	120	-	-	-	139	-	-	-	139	-	-	-	40.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	1.5%	-7,374	-7,490	-11,125	-13,643	-15,077	-7,778	-5,715	27,918	-5,781	-5,052	-5,588	-4,584	-5,642	-6,258	-4,994	-4,511	-5,854	-5,011	-5,598	-5,364	-5,489
Share Based Compensation	48.7%	1,378	927	921	1,001	993	979	970	425	421	448	411	459	376	384	288	210	372	311	391	277	316
Cashflow From Investing	-Infinity%	-11.00	-	-30.00	-47.00	-76.00	-16.00	-73.00	-270	-7.00	-	-68.00	-61.00	-4.00	-245	-	-	-	-5.00	-	-8.00	-51.00
Cashflow From Financing	1138.9%	14,768	1,192	2,860	10,048	770	4,893	1,575	16,663	-22.00	801	5,776	14,304	14,340	21,829	-230	52,035	2,542	-44.00	350	15,016	1,792

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ATNM Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue
Operating expenses:
Research and development, net of reimbursements	6,635	7,849
General and administrative	2,962	3,735
Total operating expenses	9,597	11,584
Loss from operations	(9,597)	(11,584)
Other income:
Interest income - net	927	547
Total other income	927	547
Net loss	$ (8,670)	$ (11,037)
Net loss per share of common stock – basic (in Dollars per share)	$ (0.31)	$ (0.43)
Weighted average shares of common stock outstanding – basic (in Shares)	27,886,486	25,696,623
Revenue
Revenue:
Total revenue
Other Revenue
Revenue:
Total revenue

ATNM Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 84,057	$ 76,677
Prepaid expenses and other current assets	1,316	1,586
Total Current Assets	85,373	78,263
Property and equipment, net of accumulated depreciation of $760 and $694	496	550
Restricted cash – long term	316	313
Operating leases right-of-use assets	2,140	2,289
Finance leases right-of-use assets	27	30
Total Assets	88,352	81,445
Current Liabilities:
Accounts payable and accrued expenses	7,513	7,953
Operating leases current liability	540	530
Finance leases current liability	11	11
Total Current Liabilities	8,064	8,494
Long-term license revenue deferred	35,000	35,000
Long-term operating lease obligations	1,414	1,553
Long-term finance lease obligations	17	19
Total Liabilities	44,495	45,066
Commitments and contingencies
Stockholders’ Equity:
Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding
Common stock, $0.001 par value; 1,000,000,000 shares authorized; 29,396,411 and 27,634,213 shares issued and outstanding, respectively	29	28
Additional paid-in capital	390,081	373,934
Accumulated deficit	(346,253)	(337,583)
Total Stockholders’ Equity	43,857	36,379
Total Liabilities and Stockholders’ Equity	$ 88,352	$ 81,445

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.

CEO	Mr. Sandesh C. Seth M.B.A., M.S., MBA
WEBSITE	actiniumpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	49

Actinium Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Actinium Pharmaceuticals Inc? What does ATNM stand for in stocks?

ATNM is the stock ticker symbol of Actinium Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Actinium Pharmaceuticals Inc (ATNM)?

As of Thu May 02 2024, market cap of Actinium Pharmaceuticals Inc is 260.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATNM stock?

You can check ATNM's fair value in chart for subscribers.

What is the fair value of ATNM stock?

You can check ATNM's fair value in chart for subscribers. The fair value of Actinium Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Actinium Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATNM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Actinium Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ATNM is over valued or under valued. Whether Actinium Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Actinium Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATNM.

What is Actinium Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, ATNM's PE ratio (Price to Earnings) is -5.6 and Price to Sales (PS) ratio is 3.21 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATNM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Actinium Pharmaceuticals Inc's stock?

In the past 10 years, Actinium Pharmaceuticals Inc has provided -0.3 (multiply by 100 for percentage) rate of return.